10.16
+2.94%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Labway Clinical Laboratory Co
Its shares trade on Shenzhen under the ticker 301060.SZ. It has been listed since 13 September 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.45bn and a net loss of CN¥30.7m. At that date it held total assets of CN¥2.29bn and shareholders' equity of CN¥1.55bn.
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the provision of medical and pathological examination services. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-09-13. The firm's businesses include medical testing and pathological diagnosis services and the sales of in vitro diagnosis product. The medical examination and pathological diagnosis services include pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination and physical and chemical examination. The in vitro diagnostic products sales include in vitro diagnostic instruments, reagents and related accessories and consumables.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 13 Sept 2021
- Employees
- 1,878
- Website
- labway.cn ↗
Leadership
Pay as last reported
- Mr. Weixiong ZengChairman of the Board, General Manager
- Ms. Haiyang WangFinance Director, Director, since 2024
- Mr. Zhisen MaoDeputy General Manager, since 2025
- Mr. Chuanjiang WuDeputy General Manager
- Mr. Wenjun GaoSecretary of the Board, since 2022
- Ms. Huijuan JingDirector
- Mr. Huiping JiangIndependent Director
- Mr. Guohua QiuIndependent Director
- Mr. Daojin ShiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai Labway Clinical Laboratory employs 1,878 full-time employees in Shanghai, China.
- The company provides comprehensive medical testing services including molecular and biochemical examinations.
- Shanghai Labway offers in vitro diagnostic instruments and reagents sales in the Chinese market.
Weaknesses
- Shanghai Labway's IPO was on 13 September 2021, a relatively recent listing.
- The company's business is limited to medical testing and in vitro diagnostic products in China.
- Shanghai Labway has no international presence beyond China's domestic market.
Opportunities
- The growing demand for medical testing services in China presents expansion opportunities.
- Increasing sales of in vitro diagnostic products in the Chinese healthcare sector.
- Shanghai Labway can leverage its Shanghai headquarters for regional healthcare partnerships.
Threats
- Competition from established Chinese healthcare providers in Shanghai.
- Regulatory changes in China's healthcare industry could impact operations.
- Economic downturns in China may reduce healthcare spending by consumers.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.